Published on May 26, 2026
Lucis, a Paris-based startup, has made significant strides in the preventive health sector. The platform combines blood biomarker testing with an AI-driven companion app, aiming to empower users in managing their health.
Recently, Lucis raised $20 million in a Series A funding round led . This investment comes just four months after the startup secured $8.5 million in seed funding, showcasing rapid growth and interest from major investors.
The funding round also saw participation from General Catalyst, Y Combinator, and notable angel investors, including Céline Lazorthes. These funds will be used to enhance the app’s features and expand user accessibility across Europe.
This financial boost positions Lucis to take a significant role in the preventive health landscape. With an emphasis on personalized health management, the startup is poised to change how individuals approach their well-being.
Related News
- Google Invests $40 Billion in Anthropic to Strengthen A.I. Capabilities
- Interest Peaks as Luna Band Waitlist Opens for Unique Screenless Fitness Tracker
- AI Text Detectors Under Scrutiny: A High Rate of False Negatives
- Xbox Update Allows Users to Customize Quick Resume Feature
- TikTok and Visa Unveil Debit Card to Streamline Creator Earnings in the UK
- SelectPrism Transforms Hiring with AI-Powered Agents